NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Dapagliflozin Post Marketing Surveillance in HF and CKD

CompletedN/A

Sponsor: AstraZeneca

Conditions: Heart Failure, Chronic Kidney Disease

Countries: South Korea

This is an observational, non-interventional, single-arm multicenter study. The objectives of this study are to assess safety and effectiveness of Forxiga in a real world setting in patients who are prescribed with the study drug according to the newly approved indications in the Republic of Korea

Eligibility overview

Sex: ALL

Age: 19 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients aged 19 years old and older
* Patients eligible for the product treatment (i.e. on-label treatment) according to the newly approved HF and/or CKD label in Korea
* Provision of signed and dated written informed consent by the patient or legally acceptable representative

Exclusion Criteria:

* Participation in any interventional trial during the treatment with the product.
* Any off-label indications that are not in accordance with the newly approved label in Korea.
* Any contraindications for the use of the product (as described in the local prescribing information).
* Prior use of product, as per local MFDS guidance.

Locations (26)

Busan, South Korea
Busan, South Korea
Busan, South Korea
Changwon, South Korea
Changwon, South Korea
Daegu, South Korea
Daegu, South Korea
Daejeon, South Korea
Daejeon, South Korea
Daejeon, South Korea
Gwangju, South Korea
Iksan, South Korea
Jeonju, South Korea
Jeonju, South Korea
Seongnam-si, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Suncheon, South Korea
Suwon, South Korea
Uijeongbu-si, South Korea